Disposition of 16610 shares by Greg Zante of Viking Therapeutics at 83.34 subject to Rule 16b-3
| VKTX Stock | USD 26.00 0.34 1.33% |
Slightly above 53% of Viking Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Viking Therapeutics suggests that some traders are interested. Viking Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Viking Therapeutics' earnings reports, geopolitical events, and overall market trends.
Filed transaction by Viking Therapeutics Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Viking Therapeutics Fundamental Analysis
We analyze Viking Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viking Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viking Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Viking Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Viking Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Viking Therapeutics stock to make a market-neutral strategy. Peer analysis of Viking Therapeutics could also be used in its relative valuation, which is a method of valuing Viking Therapeutics by comparing valuation metrics with similar companies.
Peers
Viking Therapeutics Related Equities
| VSTM | Verastem | 3.73 | ||||
| TERN | Terns Pharmaceuticals | 2.51 | ||||
| TGTX | TG Therapeutics | 2.36 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.86 | ||||
| AXSM | Axsome Therapeutics | 1.17 |
Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.